April 17, 2026 08:14 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bengal SIR: Supreme Court allows voters restored by tribunal till April 21 and 27 to vote | 'Women won't spare you': PM Modi warns Opposition over resistance to quota bill | Vijay booked in 3 cases over poll code violation ahead of Tamil Nadu polls | 'Black law': Stalin burns copy of 'delimitation' bill, slams Modi govt | TCS halts Nashik BPO operations amid sexual abuse, conversion allegations | ‘We are surprised’: SC stays Pawan Khera’s bail over remarks on Himanta Biswa Sarma’s wife | Historic shift: Bihar gets first BJP CM as Samrat Choudhary takes oath | 'ECI deviated from Bihar procedure': Supreme Court raises concerns over voter deletion in Bengal SIR | Noida workers’ protest turns violent: Stones pelted, vehicles damaged over wage hike demand | Oil prices jump above $103 a barrel as US moves to block Iran-linked shipping
Covid-19 Vaccine

Vaccine by itself will not end coronavirus pandemic: WHO Chief

| @indiablooms | Nov 17, 2020, at 04:20 am

Geneva/IBNS: World Health Organization (WHO) chief Tedros Adhanom Ghebreyesus on Monday said a vaccine would not by itself stop the coronavirus pandemic and cannot replace the other tools.

In a tweet, he said: A vaccine on its own will not end the COVID19 pandemic. We will still need to continue."

"Since the beginning of the COVID19 pandemic, we knew that a vaccine would be essential for bringing the pandemic under control. But it’s important to emphasise that a vaccine will complement the other tools we have, not replace them."

The remarks come on a day when American biotechnology company Moderna, Inc, said that its vaccine candidate against COVID-19 has shown 94.5 per cent efficiency.

The WHO chief mentioned that: "Initial supply of COVID19 vaccines will be limited, so healthworkers, older people & other at-risk populations will be prioritised. That will hopefully reduce the number of deaths & enable health systems to cope, but the virus will still have a lot room to move."

Moderna's study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID).

This first interim analysis was based on 95 cases, of which 90 cases of COVID-19 were observed in the placebo group versus 5 cases observed in the mRNA-1273 group, resulting in a point estimate of vaccine efficacy of 94.5% (p <0.0001).

Welcoming the progress, Stéphane Bancel, Chief Executive Officer of Moderna, said: “This is a pivotal moment in the development of our COVID-19 vaccine candidate. Since early January, we have chased this virus with the intent to protect as many people around the world as possible. This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease."

Bancel said, “This milestone is only possible because of the hard work and sacrifices of so many."
 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.